αcD2 mAb treatment safely attenuates adoptive transfer colitis

Laboratory Investigation

Volumn 85, Issue 8, 2005, Pages 1013-1023

  Pawlowski, Nina N ^a   Kakirman, Hacer ^b   Kühl, Anja A ^a   Liesenfeld, Oliver ^c   Grollich, Katja ^a   Loddenkemper, Christoph ^a   Zeitz, Martin ^a   Hoffmann, Jörg C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c Institut für Infektionsmedizin   (Germany)

Author keywords

CD2; Immunomodulation; Safety; Toxoplasma gondii; Transfer colitis

Indexed keywords

ALPHACD2 MONOCLONAL ANTIBODY; DEXAMETHASONE; IMMUNOGLOBULIN G; INTERLEUKIN 2; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CD2 ANTIGEN; LEUKOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; HEMATOCHEZIA; IMMUNE RESPONSE; MOUSE; NONHUMAN; PARASITE CONTROL; PRIORITY JOURNAL; T LYMPHOCYTE; TOXOPLASMA GONDII; ADOPTIVE TRANSFER; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; ENTERITIS; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE; PATHOLOGY; SPLEEN; TOXOPLASMOSIS;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD2; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-2; LYMPHOCYTES; MICE; MICE, INBRED C57BL; SPLEEN; TOXOPLASMOSIS;

EID: 27144440483     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700295     Document Type: Article

References (57)

1. Autschbach F, Schürmann G, Qiao L, et al. Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease. Virchows Arch 1995;426:51-60.
2. Boirivant M, Marini M, Di Felice G, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999;116:557-565.
3. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999;163:1081-1090.
4. Sans M, Panes J, Ardite E, et al. VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology 1999;116:874-883.
5. Farkas S, Herfarth H, Rossle M, et al. Quantification of mucosal leucocyte endothelial cell interaction by in vivo fluorescence microscopy in experimental colitis in mice. Clin Exp Immunol 2001;126:250-258.
6. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261-1270.
7. Kakazu T, Hara J, Matsumoto T, et al. Type 1 T-helper cell predominance in granulomas of Crohn's disease. Am J Gastroenterol 1999;94:2149-2155.
8. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549.
9. van der Merwe PA. Formation and function of the immunological synapse. Curr Opin Immunol 2002;14:293-298.
10. van der Merwe PA, Davis SJ. Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 2003;21:659-684.
11. Shaw S, Luce GE, Quinones R, et al. Two antigen-independent adhesion pathways used by human cytotoxic T-cell clones. Nature 1986;323:262-264.
12. Bierer BE, Peterson A, Gorga JC, et al. Synergistic T cell activation via the physiological ligands for CD2 and the T cell receptor. J Exp Med 1988;168:1145-1156.
13. Pirzer UC, Schürmann G, Post S, et al. Differential responsiveness to CD3-Ti vs. CD2-dependent activation of human intestinal T lymphocytes. Eur J Immunol 1990;20:2339-2342.
14. Zeitz M, Quinn TC, Graeff AS, et al. Mucosal T cells provide helper function but do not proliferate when stimulated by specific antigen in lymphogranuloma venereum proctitis in nonhuman primates. Gastroenterology 1988;94:353-366.
15. Targan SR, Deem RL, Liu M, et al. Definition of a lamina propria T cell responsive state. Enhanced cytokine responsiveness of T cells stimulated through the CD2 pathway. J Immunol 1995;154:664-675.
16. Boirivant M, Pica R, DeMaria R, et al. Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. J Clin Invest 1996;98:2616-2622.
17. Itoh J, Kugathasan T, McCormick T, et al. Resistence of Crohn's disease (CD) mucosal T-cells to cell death is independent of trigger: Decreased anti-Fas and nitric oxide (NO)-induced apoptosis. Gastroenterology 1998;114:G1553.
18. Wakkach A, Cottrez F, Groux H. Differentiation of regulatory T cells 1 is induced by CD2 costimulation. J Immunol 2001;167:3107-3113.
19. Bullens DM, Rafiq K, Charitidou L, et al. Effects of co-stimulation by CD58 on human T cell cytokine production: a selective cytokine pattern with induction of high IL-10 production. Int Immunol 2001;13:181-191.
20. Krensky AM, Sanchez-Madrid F, Robbins E, et al. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL- target interactions. J Immunol 1983;131:611-616.
21. Palacios R, Martinez Maza O. Is the E receptor on human T lymphocytes a 'negative signal receptor'? J Immunol 1982;129:2479-2485.
22. Chavin KD, Qin L, Yon R, et al. Anti-CD2 mAbs suppress cytotoxic lymphocyte activity by the generation of Th2 suppressor cells and receptor blockade. J Immunol 1994;152:3729-3739.
23. Peng X, Kasran A, Bullens D, et al. Ligation of CD2 provides a strong helper signal for the production of the type 2 cytokines interleukin-4 and -5 by memory T cells. Cell Immunol 1997;181:76-85.
24. Gray JD, Hirokawa M, Ohtsuka K, et al. Generation of an inhibitory circuit involving CD8+ T cells, IL-2, and NK cell-derived TGF-beta: contrasting effeccts of anti-CD2 and anti-CD3. J Immunol 1998;160:2248-2254.
25. Chavin KD, Lau HT, Bromberg JS. Prolongation of allograft and xenograft survival in mice by anti-CD2 monoclonal antibodies. Transplantation 1992;54:286-291.
26. Przepiorka D, Phillips GL, Ratanatharathorn V, et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 1998;92:4066-4071.
27. Mourad M, Besse T, Malaise J, et al. BTI-322 for acute rejection after renal transplantation. Transplant Proc 1997;29:2353.
28. Haga M, Hirahara H, Tsuchida M, et al. Costimulatory signal blockade by anti-CD2 monoclonal antibody in combination with 15-deoxyspergualin prolongs concordant xenograft survival. Transplant Proc 2000;32:1006-1008.
29. Hoffmann JC, Herklotz C, Zeidler H, et al. Anti-CD2 (OX34) MoAb treatment of adjuvant arthritic rats: attenuation of established arthritis, selective depletion of CD4+ T cells, and CD2 down-modulation. Clin Exp Immunol 1997;110:63-71.
30. Hoffmann JC, Herklotz C, Zeidler H, et al. Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) OX34. Ann Rheum Dis 1997;56:716-722.
31. Jung S, Toyka K, Hartung HP. Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2. Eur J Immunol 1995;25:1391-1398.
32. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-255.
33. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med 2001;345:1098-1104.
34. Liesenfeld O, Kosek J, Remington JS, et al. Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J Exp Med 1996;184:597-607.
35. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491-501.
36. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-1290.
37. Powrie F, Leach MW, Mauze S, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994;1:553-562.
38. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035.
39. Van Assche G, Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis 2002;8:291-300.
40. Mullin GE, Lazenby AJ, Harris ML, et al. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992;102:1620-1627.
41. Powrie F, Leach MW, Mauze S, et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993;5:1461-1471.
42. Rudolphi A, Boll G, Poulsen SS, et al. Gut-homing CD4+ T cell receptor alpha beta+ T cells in the pathogenesis of murine inflammatory bowel disease. Eur J Immunol 1994;24:2803-2812.
43. Bregenholt S, Reimann J, Claesson MH. Proliferation and apoptosis of lamina propria CD4+ T cells from scid mice with inflammatory bowel disease. Eur J Immunol 1998;28:3655-3663.
44. Burns RC, Rivera-Nieves J, Moskaluk CA, et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 2001;121:1428-1436.
45. Hoffmann JC, Peters K, Henschke S, et al. Role of T lymphocytes in rat 2,4,6-trinitrobenzene sulphonic acid (TNBS) induced colitis: increased mortality after gammadelta T cell depletion and no effect of alphabeta T cell depletion. Gut 2001;48:489-495.
46. Chavin KD, Qin L, Lin J, et al. Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production. Ann Surg 1993;218:492-501.
47. Gonsky R, Deem RL, Hughes CC, et al. Activation of the CD2 pathway in lamina propria T cells up-regulates functionally active AP-1 binding to the IL-2 promoter, resulting in messenger RNA transcription and IL-2 secretion. J Immunol 1998;160:4914-4922.
48. Lin J, Yon RW, Chavin KD, et al. Anti-CD2 monoclonal antibody-induced receptor changes: down modulation of cell surface CD2. Transplantation 1995;59:1162-1171.
49. Chavin KD, Qin L, Lin J, et al. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. Transplantation 1993;55:901-908.
50. Reed JC, Tadmori W, Kamoun M, et al. Suppression of interleukin 2 receptor acquisition by monoclonal antibodies recognizing the 50 KD protein associated with the sheep erythrocyte receptor on human T lymphocytes. J Immunol 1985;134:1631-1639.
51. Gückel B, Berek C, Lutz M, et al. Anti-CD2 antibodies induce T cell unresponsiveness in vivo. J Exp Med 1991;174:957-967.
52. Evans CF, Rall GF, Killeen N, et al. CD2-deficient mice generate virus-specific cytotoxic T lymphocytes upon infection with lymphocytic choriomeningitis virus. J Immunol 1993;151:6259-6264.
53. Beck JM, Blackmon MB, Rose CM, et al. T cell costimulatory molecule function determines susceptibility to infection with Pneumocystis carinii in mice. J Immunol 2003;171:1969-1977.
54. Liesenfeld O, Kang H, Park D, et al. TNF-alpha, nitric oxide and IFN-gamma are all critical for development of necrosis in the small intestine and early mortality in genetically susceptible mice infected perorally with Toxoplasma gondii. Parasite Immunol 1999;21:365-376.
55. Chavin KD, Qin L, Lin J, et al. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model. J Immunol 1993;151:7249-7259.
56. Woodward JE, Qin L, Chavin KD, et al. Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways. Transplantation 1996;62:1011-1018.
57. Qin L, Chavin KD, Lin J, et al. Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival. J Exp Med 1994;179:341-346.